Literature DB >> 23665320

The expression of IL-6 and STAT3 might predict progression and unfavorable prognosis in Wilms' tumor.

Li-Juan Zhang1, Wei Liu, Ying-Mao Gao, Ye-Jun Qin, Rong-De Wu.   

Abstract

PURPOSE: To investigate the expression profiles of IL-6 and STAT3 in Wilms' tumor (WT) and their relationship with disease progression.
METHODS: Immunohistochemistry was used to examine IL-6 and STAT3 expression in 58 primary tumors and 18 invasive/metastatic ones.
RESULTS: Positive expression rate of IL-6/STAT3 was 39.7% (23/58)/29.3% (17/58) in primary WT tissues, while 61.1% (11/18)/33.3% (6/18) in associated invasive/metastatic tissues. The expression rate of IL-6 and STAT3 was higher in primary WT tumors of invasive/metastatic group than that of non-invasive/metastatic group (P=0.033; P=0.012). There was a positive correlation between IL-6 and STAT3 expression in 76 WT tissues (P<0.001, r=0.444). The expression of IL-6 /STAT3 between primary WT and matched invasive/metastatic tissues was concordance (P=0.727; P=0.99). IL-6 expression status and histopathological type were associated with disease-free survival (DFS) and overall survival (OS) (P<0.05), while STAT3 was only correlated with DFS (P<0.05).
CONCLUSIONS: IL-6 and STAT3 expression in WT might be correlated with progression and predict unfavorable prognosis, highlighting a new therapy target for invasive or metastatic WTs.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665320     DOI: 10.1016/j.bbrc.2013.04.102

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures.

Authors:  Hongyu Kong; Qiongwen Zhang; Yunhui Zeng; Hong Wang; Mengqian Wu; Tianying Zheng; Yanzhang Zeng; Huashan Shi
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  The roles of microRNAs in Wilms' tumors.

Authors:  Xin Yu; Zheng Li; Matthew T V Chan; William Ka Kei Wu
Journal:  Tumour Biol       Date:  2015-12-03

Review 3.  Biomarkers for Wilms Tumor: A Systematic Review.

Authors:  Eugene B Cone; Stewart S Dalton; Megan Van Noord; Elizabeth T Tracy; Henry E Rice; Jonathan C Routh
Journal:  J Urol       Date:  2016-05-31       Impact factor: 7.450

4.  Investigating the dysfunctional pathogenesis of Wilms' tumor through a multidimensional integration strategy.

Authors:  Wenbiao Chen; Jia Zhuang; Lan Gong; Yong Dai; Hongyan Diao
Journal:  Ann Transl Med       Date:  2019-04

5.  Comprehensive Analysis of a Long Noncoding RNA-Associated Competing Endogenous RNA Network in Wilms Tumor.

Authors:  Feng Zhang; Liping Zeng; Qinming Cai; Zihao Xu; Ruida Liu; Haicheng Zhong; Robert Mukiibi; Libin Deng; Xiaoli Tang; Hongbo Xin
Journal:  Cancer Control       Date:  2020 Apr-Jun       Impact factor: 3.302

6.  The effects of interval aerobic training on mesenchymal biomarker gene expression, the rate of tumor volume, and cachexia in mice with breast cancer.

Authors:  Samira Gholamian; Seyyed Reza Attarzadeh Hosseini; Amir Rashidlamir; Hamid Aghaalinejad
Journal:  Iran J Basic Med Sci       Date:  2020-02       Impact factor: 2.699

Review 7.  Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review).

Authors:  Elena Niculet; Valentin Chioncel; Alina M Elisei; Magdalena Miulescu; Olimpia D Buzia; Lawrence C Nwabudike; Mihaela Craescu; Miruna Draganescu; Florin Bujoreanu; Elisabeta Marinescu; Manuela Arbune; Diana Sabina Radaschin; Carmen Bobeica; Aurel Nechita; Alin L Tatu
Journal:  Exp Ther Med       Date:  2021-01-25       Impact factor: 2.447

Review 8.  Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers.

Authors:  Nilay Shah
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 9.  Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis.

Authors:  Pin Wu; Dang Wu; Lufeng Zhao; Lijian Huang; Gang Shen; Jian Huang; Ying Chai
Journal:  Oncotarget       Date:  2016-04-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.